Although anti-HER2 monoclonal antibodies (mAbs) (e.g., trastuzumab) are presently described as one of the furthermost effective therapeutics in oncology, substantial numbers of patients with HER2-overexpressing tumors, such as breast cancer, show robust resistance to this intervention [11]. The gene discussed is ERBB2; the disease is breast carcinoma.